Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 942-710-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on developmental toxicity
Description of key information
The NOAEL of CJ302 in rat’s maternal toxicity, or teratogenic and embyo-/fetotoxicity performance was 1000 mg/kg/day (OECD TG414).
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From April 18, 2018 to March 01, 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- - Source: Beijing Vital River Laboratory Animal Technology Co., Ltd.
- Age at study initiation: 84-90 days old
- Weight at study initiation: Males: 402-475 g; Females: 234-309 g
- Housing: There were two rats at most per cage, and mated females were housed individually in cages.
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 6 days
- Temperature (°C): 21.7-24.0 °C
- Humidity (%): 46-73 %
- Photoperiod: 12-hrs dark / 12-hrs light - Route of administration:
- oral: gavage
- Vehicle:
- water
- Analytical verification of doses or concentrations:
- yes
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Solvent control
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Remarks:
- Low-dose level
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Remarks:
- Mid-dose level
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- High-dose level
- No. of animals per sex per dose:
- For Solvent control: 31, females
For Low-dose level: 30, females
For Mid-dose level: 30, females
For High-dose level: 30, females - Control animals:
- yes, concurrent vehicle
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One rat in low-dose group (No. 2107) was dehairing on its right forelimb or/and hindlimb during GD8~20; one rat in the mid-dose group (No. 2223) was dehairing on its right breast during GD18~20; one rat in high-dose group (No. 2312) was dehairing on its right prothorax during GD6~20, and another rat (No. 2327) was dehairing on its breast during GD18~20. As dehairing in the dosed groups was incidental without dose-relationship, it is not considered to be toxicologically insignificant. Most of rats in the mid- and high- dose groups had red faeces after being administrated, but which was considered to be caused with the color of the test item and without adverse effect.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In the mid-dose group, the post-implantion loss had a significant decrease with the control group (P≤0.05), but that was considered without toxicological significance.
- Early or late resorptions:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In the mid-dose group, the percent of absorbed fetuses had a significant decrease with the control group (P≤0.05), but that was considered without toxicological significance.
- Dead fetuses:
- no effects observed
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- dead fetuses
- early or late resorptions
- food consumption and compound intake
- mortality
- pre and post implantation loss
- water consumption and compound intake
- Fetal body weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A statistically significant increase in the body weight of live fetuses was observed in the low- and mid- dose groups compared with the control group (P≤0.05 or P≤0.01), but that was considered without toxicological significance.
- Changes in sex ratio:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- One fetus in the low-dose group showed signs of incomplete ossification of skull bone, but the frequency of these abnormalities in the dose groups had no significant difference compared with the control group (P>0.005) and which were considered as incidental findings. Some examined fetuses had less than six sternal ossification points, but there was no difference in the mean number of sternal ossification points in all dose groups (P>0.05).
- Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- 4, 2 and 2 fetuses in the control group, mid- and high- dose group showed signs of hydronephrosis in one or double kindeys, but the frequency of these abnormalities in the dose groups had no significant difference compared with the control group (P>0.005) and which were considered as incidental findings.
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- changes in sex ratio
- fetal/pup body weight changes
- external malformations
- skeletal malformations
- visceral malformations
- Abnormalities:
- no effects observed
- Developmental effects observed:
- no
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Treatment related:
- no
- Conclusions:
- According to OECD 414 test method, the no observed adverse effect level of CJ302 in rat’s maternal toxicity, or teratogenic and embyo-/fetotoxicity performance was 1000 mg/kg.d.
- Executive summary:
This test using the procedures outlined in the SYRICI Study Plan for G1863B0030 and OECD 414. There were thirty or thirty-one mated female rats in each group, which resulted in 31, 29, 26 and 27 pregnant rats in vehicle control group and the low-, mid- and high-, respectively. CJ302 (100, 300 or 1000 mg/kg.d.) was given orally by gavage daily during the day 5~19 of pregnancy (GD5~19), and were euthanized with CO2 on GD20.
No deaths or treatment-related clinical toxicity were observed in the course of this study. Most of rats in the mid- and high-dose groups had red faeces after being administrated, but which was considered to be caused with the color of CJ302 and without adverse effect. During the administration period, the mean body weights and body weight change of pregnant rats in all dosed groups had no statistically significant difference compared with the control group. At the same time, no significant effect in food aonsumption of the pregnant rat during the treated period was observed in all dose groups. In all dose groups, no adverse effect was observed in all prenatal reproductive parameters.
The fetal examination showed that no adverse effect in body weight and sex distribution of live fetuses was observed in all dosed group. No adverse effect attribution to treatment was observed across all groups with respect to examined, soft-tissue and skeletal malformations or variations except that some examined fetuses had less than six sternal ossification points, but there was no difference in the mean number of sternal ossification points in all dosed groups as compared with the control group.
Therefore, the no observed adverse effect levelof CJ302 in rat’s maternal toxicity, or teratogenic and embyo-/fetotoxicity performance was 1000 mg/kg.d.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
Effect on developmental toxicity: via oral route
There were thirty or thirty-one mated female rats in each group, which resulted in 31, 29, 26 and 27 pregnant rats in vehicle control group and the low-, mid- and high-, respectively. CJ302 (100, 300 or 1000 mg/kg.d.) was given orally by gavage daily during the day 5~19 of pregnancy (GD5~19), and were euthanized with CO2 on GD20.
No deaths or treatment-related clinical toxicity were observed in the course of this study. Most of rats in the mid- and high-dose groups had red faeces after being administrated, but which was considered to be caused with the color of CJ302 and without adverse effect. During the administration period, the mean body weights and body weight change of pregnant rats in all dosed groups had no statistically significant difference compared with the control group. At the same time, no significant effect in food aonsumption of the pregnant rat during the treated period was observed in all dose groups. In all dose groups, no adverse effect was observed in all prenatal reproductive parameters.
The fetal examination showed that no adverse effect in body weight and sex distribution of live fetuses was observed in all dosed group. No adverse effect attribution to treatment was observed across all groups with respect to examined, soft-tissue and skeletal malformations or variations except that some examined fetuses had less than six sternal ossification points, but there was no difference in the mean number of sternal ossification points in all dosed groups as compared with the control group.
Therefore, the no observed adverse effect level of CJ302 in rat’s maternal toxicity, or teratogenic and embyo-/fetotoxicity performance was 1000 mg/kg.d.
Justification for classification or non-classification
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
